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CASE REPORT
Kasabach-Merritt Syndrome Arising from Tufted 
Angioma Successfully Treated with Systemic 
Corticosteroid
Taegyun Kim, M.D., Mi Ryung Roh, M.D., Soohyun Cho, M.D., Kee Yang Chung, M.D.
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
We report a case of Kasabach-Merritt syndrome arising from 
a tufted angioma successfully treated with systemic 
corticosteroid. A 2-month-old male infant presented with a 
palm-sized, erythematous induration on his left pubis. The 
lesion was diagnosed as tufted angioma histopathologically. 
After 1 month, the lesion suddenly expanded to the abdomen 
and scrotum. Initial laboratory tests were consistent with 
consumptive coagulopathy. He was diagnosed with 
Kasabach-Merritt syndrome and treated with intravenous 
dexamethasone at 0.32 mg/kg/day (equivalent to predni-
solone 2.0 mg/kg/day). Two days after initiating the treat-
ment, his platelet counts recovered and the lesion ceased to 
expand. Steroid therapy was converted to oral prednisolone 
and the dosage was subsequently tapered, and the lesion 
gradually involuted with no signs of recurrence for a year. 
(Ann Dermatol 22(4) 426∼430, 2010)
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INTRODUCTION
Kasabach-Merritt syndrome (KMS) is a rare complication 
of pre-existing hemangioma in infancy and early child-
hood1. Patients with KMS present with an enlarged 
hemangioma and laboratory features of thrombocytopenia 
and consumptive coagulopathy. KMS is associated with 
several types of hemangiomas in infancy, including kapo-
siform hemangioendothelioma (KHE), tufted angioma, and 
infantile hemangioma. Among those hemangiomas, KHE 
occurs most frequently before KMS2. Tufted angioma is a 
benign vascular tumor characterized by histopathological 
features of tufts of capillary-sized vessels within the 
dermis3. Although a recent study showed spontaneous 
regression in most cases within 2 years4, these benign 
tumors may develop potentially fatal KMS as compli-
cation2,3.
With an overall mortality rate of 12%, various treatment 
regimens have been introduced to manage KMS5. Recent 
reports recommended a careful stepwise approach in the 
management of KMS, but the results demonstrated in-
consistent efficacy6,7. Among the regimens recommended, 
systemic corticosteroid is considered as first-line therapy 
for KMS patients because of its low cost and ease of 
administration6-8. We report a case of KMS arising from 
tufted angioma successfully treated with systemic corti-
costeroid.
CASE REPORT
A 2-month-old male infant presented with a skin lesion on 
his left pubis 2 weeks after birth. He had no complications 
during birth. Physical examination revealed a solitary, 
2.5×2.5 cm-sized, erythematous induration on his left 
pubis (Fig. 1A). A 3 mm punch biopsy was performed at 
the center of the lesion. Histopathological examination 
demonstrated well-circumscribed lobules composed of 
capillaries resembling “cannonballs” within the dermis. 
The lobules were composed of small dilated capillaries 
surrounded by crescent-shaped vascular structures. The 
lesion was diagnosed as tufted angioma (Fig. 2).
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Fig. 1. (A) A solitary 2.5×2.5
cm-sized bluish, growing indurated 
subcutaneous nodule on the left 
pubis. (B) A large, well-defined 
purpuric induration expanded to the
abdomen, scrotum and left thigh.
Fig. 2. (A) Cannon ball distribution 
of small discrete vascular tufts are 
found throughout the dermis (H&E, 
×40). (B) A lobule composed of 
bloodless aggregates of round 
dilated capillaries surrounded by 
crescent-shaped vascular structures 
(H&E, ×200).
Fig. 3. Slightly bluish and erythematous induration of involuted
lesion 3 months after treatment.
One month following skin biopsy, the lesion suddenly 
expanded to the abdomen and scrotum (Fig. 1B). Physical 
examination revealed a purpuric and firm induration 
covering the lower half of the left abdomen, pubis, 
scrotum and upper to medial thigh. The initial laboratory 
work-up revealed severe thrombocytopenia (platelet 
counts, 61,000/mm3); increased D-dimer (15,335 ng/ml, 
reference range: 0∼243 ng/ml); increased fibrin degrad-
ation products (1:8∼16 positive, reference: 1:2 negative) 
and decreased fibrinogen (67 mg/dl, reference range: 200
∼400 mg/dl), suggestive of consumptive coagulopathy. 
Abdominal ultrasound imaging study revealed mild 
hepatomegaly. Other laboratory results including white 
blood cell counts, hemoglobin, bleeding time, coagulat-
ion time, prothrombin time (PT), antithrombin III, and 
activated partial thromboplastin time (aPTT) were within 
the normal range. He was diagnosed with KMS arising 
from a pre-existing tufted angioma based on the clinical 
findings and laboratory values. The patient was admitted 
to commence immediate treatment with intravenous 
dexamethasone at 0.32 mg/kg/day (equivalent to predni-
solone 2.0 mg/kg/day). Two days after initiating therapy, 
his platelet counts recovered to 222,000/mm3 and the 
lesion ceased to expand. Subsequently, intravenous 
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Table 1. A stepwise approach in the treatment of Kasabach-Merritt syndrome
Doses
First-line treatment
  Systemic corticosteroid 1) Oral prednisolone 2 to 3 mg/kg/day16
2) Oral prednisolone 5 mg/kg/day*
3) Oral methylprednisolone 30 mg/kg/day for 5 days, tapered gradually every 5 days to 20, 10, 5, 
2.5, and finally to 1 mg/kg/day†
Second-line treatment
  Interferon-alpha5,7,15 3 Mu/m2/day, subcutaneously
  Vincristine7,15 1.5 mg/m2 (maximum 2 mg), intravenously, weekly for 4 weeks
  Radiotherapy‡ 100 to 2,400 cGy
*It was more effective than prednisolone at a dose of 3 mg/kg/day in one study17. †It seemed to achieve high rate of initial response 
as well as short duration of therapy18. ‡It should be considered for patients with life-threatening lesions or with lesions that might 
compromise organ function or if other therapies fail to achieve a response5,15. Our case: Intravenous dexamethasone 0.32 mg/kg/day 
(equivalent to prednisolone 2 mg/kg/day) for 2 days, gradually tapered to oral prednisolone at a dose of 1.5, 1.2, 1.0 over 15 days, 
and 0.5 mg/kg/day over two weeks.
dexamethasone was changed to oral prednisolone, then 
gradually tapered to 1.5, 1.2, 1.0 mg/kg/day over 15 days 
and finally to 0.5 mg/kg/day over two weeks. The wide 
purpuric induration was shrunken to a small bluish, 
erythematous induration (Fig. 3). Then, treatment was 
stopped and the patient showed no signs of recurrence for 
a year. There were no remarkable complications related to 
systemic corticosteroid during the treatment and follow up 
period.
DISCUSSION
KMS is a rare complication of pre-existing hemangiomas 
first described by Kasabach and Merritt1 in 1940. It is 
characterized by an enlarging hemangioma, associated 
with thrombocytopenia and consumptive coagulopathy 
which may lead to life-threatening bleeding1. More than 
80% of cases occur within the first year of life9. KMS can 
be a complication of KHE, tufted angiomas or, rarely, 
large infantile hemangiomas but most reported cases of 
KMS were associated with KHE and tufted angiomas2. A 
recent retrospective study conducted by Enjolras et al.10 
revealed that KMS was due either to KHE and/or tufted 
angiomas. The residual lesions of patients with cured KMS 
were predominantly tufted angiomas, whereas KHE was 
more common during the active phase of KMS. Thus it is 
possible that KHE and tufted angiomas are the part of the 
same neoplastic spectrum and histologic continuum11. 
Enjolras et al.10 proposed that KMS was not a compli-
cation of infantile hemangiomas, but of KHE and tufted 
angiomas based on their findings.
The trigger factors for the development of KMS include 
surgical intervention, pregnancy, angiography, and needle 
aspiration of hemangioma12-14. In our case, KMS occurred 
one month after 3 mm skin biopsy from a pre-existing 
tufted angioma. Minor trauma due to punch biopsy might 
have triggered KMS in our case.
The pathogenesis of KMS remains unestablished. How-
ever, platelet trapping by abnormally proliferating endo-
thelium within the hemangioma has been proposed as a 
possible mechanism15. Platelet trapping can result in the 
activation of platelets with secondary activation of coa-
gulation cascades, eventually leading to consumption of 
various clotting factors. Immunohistochemical study using 
monoclonal antibody against CD61, a marker of platelets, 
and isotope studies using 111indium-labeled platelets and 
51Cr-labeled platelets support the possible role of platelet 
trapping in the development of KMS15. The reason why 
platelets are trapped within the hemangioma in the 
patients with KMS remains unelucidated. In addition to 
platelet trapping, excessive blood flow and sheer stress 
secondary to arteriovenous shunts within the tumors may 
cause further platelet activation. Both thrombocytopenic 
status and reduction in coagulation factors eventually 
result in bleeding within the tumors that manifests as a 
rapidly growing hemangioma.
Management of KMS has been challenging because of its 
rarity and there are no well-established systematic treat-
ment strategies to date. Systemic corticosteroid is consi-
dered to be first-line therapy in patients with KMS (Table 
1)6-8,15-18. One study demonstrated that treatment with 
prednisolone at 2 or 3 mg/kg/day achieved response in 
30% to 72% of infants16. However, other data suggested 
variable response to prednisolone, ranging from no 
efficacy to significant regression in lesion size, and even 
complete remission7. The discrepant results may be due to 
variation in patient clinical characteristics in the studies, 
such as different pre-existing tumors, and the possibility 
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that the enrolled patients actually had vascular malfor-
mations, rather than hemangiomas. If a lesion responds to 
steroid, the dose should be reduced slowly to prevent 
recurrence. High doses of prednisolone (more than 5 
mg/kg/day) can be used as an alternative, and it has 
shown to be more effective than 3 mg/kg/day in a study by 
Sadan and Wolach17. Some authors advocate the super-
iority of high dose oral methylprednisolone therapy to the 
conventional treatment with prednisolone18. High rates of 
initial response and short therapy duration appears to be 
an advantage, but should be confirmed by a double blind, 
comparative study between different regimens. The me-
chanisms of prednisolone in controlling thrombocytope-
nia, coagulopathy, and eventually stabilization of hemangi-
omas remain unclear, although it appears to increase 
platelet longevity, increase vasoconstriction, inhibit fibrin-
olysis, and disrupt angiogenesis. Side-effects associated 
with steroid treatment include hypertension, cushingoid 
appearance, growth suppression and opportunistic in-
fections15,19. Our patient commenced with 0.32 mg/kg/day 
of intravenous dexamethasone, equivalent to 2.0 mg/kg/day 
of prednisolone. The most likely cause of our patient’s 
rapid platelet recovery and lesion stabilization following 
initiating therapy was the superior bioavailability of 
intravenous steroids over that of oral administration.
In cases resistant to systemic corticosteroid, multiple 
treatment modalities can be used in a stepwise manner, 
including interferon-alpha, an antiproliferative and anti-
angiogenic agent, and vincristine, a strong inhibitor of 
angiogenesis. Radiotherapy is another option which can 
induce embolization within the hemangiomas. These 
options are usually recommended as second-line thera-
pies6,7,15. However, treatment with these regimens can 
result in severe adverse events. The known adverse effects 
of interferon therapy include flu-like symptoms, neutro-
penia, and spastic diplegia in infancy5,7. Vincristine can be 
associated with transient peripheral neuropathy, and it is 
considered a relatively safe regimen with high efficacy7,8,15. 
Since radiotherapy has been reported to induce late side 
effects, including local growth failure, late skin changes, 
destruction of bone tissue and secondary malignancies, it 
should be administered to patients with life-threatening 
lesions, or to patients with lesions that may compromise 
organ function, or when other therapies fail to achieve 
response5-7,15.
In conclusion, conventional systemic corticosteroid is 
probably the most cost-effective treatment option in 
patients with KMS. Systemic corticosteroid may result in 
variable response in KMS; however, it should be con-
sidered first-line treatment since it offers rapid resolution 
and less complications, compared to other treatment 
modalities. In addition, intravenous corticosteroid may be 
more efficacious than oral corticosteroid, most likely due 
to superior bioavailability. However, due to the rarity of 
this syndrome, it is difficult to undertake any comparative 
studies on different modalities.
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